Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Olympia Observer.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on August 1, 2025
Verathon Launches GlideScope ClearFit Video Laryngoscope Offering Cost-Effective Airway Management
EIN Presswire
·
August 1, 2025
A cover-based video laryngoscope delivering versatility and value with trusted GlideScope performance BOTHELL, WA, UNITED STATES, August 1, 2025 /EINPresswire.com/ -- Verathon®, a global leader in airway management solutions, announces the launch of …
Hims & Hers Health, Inc. (HIMS) – Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo’s Termination of Collaboration With HIMS Triggers Securities Class Actions – Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 25, 2025, investors in Hims …
Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending – Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 16, 2025, Sarepta Therapeutics (NASDAQ: SRPT) announced a major restructuring that involves, in part, a 36% workforce reduction (500 employees) and other steps to annually save about $400 million. …
The J.M. Smucker Company (SJM) Faces Investor Scrutiny After Announcing The Second Hostess-Related Impairments In About 3 Months – Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On June 10, 2025, investors in The J.M. Smucker Company (NYSE: SJM) saw the price of their shares decline over 15% after the company announced disappointing Q4 2025 financial results. This announcement has …
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune ( …
Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal -- Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Investors in Simulations Plus, Inc. (NASDAQ: SLP) saw the price of their shares decline about 25% on July 15, 2025 after the company reported its Q3 2025 $67.3 million net loss that included a $77.2 million …
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over “Inflated Guidance” – Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 …
RCKT 10-DAY DEADLINE ALERT: FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman
GlobeNewswire
·
August 1, 2025
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare …